# US 2021/0330765 A1 · Liquid neurotoxin formulation stabilized with tryptophan or tyrosine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0330765 A1
- Document ID: US20210330765A1
- Status: Published application
- Kind: A1
- Application number: 17/304,888
- Filed: 2021-06-28
- Published: 2021-10-28
- Earliest claimed: 2016-05-27
- Assignees: Ipsen Biopharm Ltd.
- Applicants: Ipsen Biopharm Limited
- Inventors: Anders JARSTAD; Anna FRIIS; Ulf STAHL; Ann GURELL; Barbro AGREN; Emilia EDSTROM; Andrew PICKETT
- Web page: https://patentgrep.com/patent/US20210330765A1

## CPC

- A61K 38/4893: {Botulinum neurotoxin (3.4.24.69)}
- A61K 8/00: Cosmetics or similar toiletry preparations
- A61K 8/19: containing inorganic ingredients
- A61K 8/20: Halogens; Compounds thereof
- A61K 8/24: Phosphorous; Compounds thereof
- A61K 8/39: Derivatives containing from 2 to 10 oxyalkylene groups
- A61K 8/44: Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
- A61K 8/492: {having condensed rings, e.g. indol}
- A61K 8/64: Proteins; Peptides; Derivatives or degradation products thereof
- A61K 8/66: Enzymes
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 47/02: Inorganic compounds
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61P 5/00: Drugs for disorders of the endocrine system
- A61P 13/00: Drugs for disorders of the urinary system
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61Q 19/00: Preparations for care of the skin
- A61Q 19/06: for countering cellulitis
- A61Q 19/08: Anti-ageing preparations
- A61K 2800/30: Characterized by the absence of a particular group of ingredients
- A61K 2800/52: Stabilizers
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The invention relates to stable liquid neurotoxin formulations which are free of animal proteins, comprising a surfactant, an amino acid selected from tryptophan and tyrosine, a buffer comprising sodium, chloride and phosphate ions, which have a pH between 5.5 and 8, and which are stable for 2 months. These compositions are suitable for use in therapy and in particular for administration to a patient to achieve a desired therapeutic or aesthetic effect. The invention also relates to the use of an amino acid selected from tryptophan and tyrosine to protect a proteinaceous neurotoxin from degradation in a liquid composition which is free of animal derived proteins.

## Claims

### Claim 1

A liquid composition comprising a proteinaceous neurotoxin, a surfactant, an amino acid selected from tryptophan and tyrosine, a buffer comprising sodium, chloride and phosphate ions,
wherein said liquid composition has a pH between 5.5 and 8,
wherein said composition is free of animal derived proteins, and
wherein said liquid composition is stable over time.

### Claim 2 (depends on 1)

A liquid composition according to claim 1, wherein said surfactant is a non-ionic surfactant.

### Claim 3 (depends on 2)

A liquid composition according to claim 2, wherein said non-ionic surfactant is a polysorbate, preferably Polysorbate 20, Polysorbate 60 or Polysorbate 80.

### Claim 4 (depends on 1, 2, 3)

A liquid composition according to any one of claims 1 to 3, wherein said amino acid is tryptophan, preferably L-tryptophan.

### Claim 5 (depends on 1, 2, 3, 4)

A liquid composition according to any one of claims 1 to 4, wherein said buffer further comprises potassium ions.

### Claim 6 (depends on 1, 2, 3, 4, 5)

A liquid composition according to any one of claims 1 to 5, wherein said composition has a pH between 6.0 and 7.5.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

A liquid composition according to any one of claims 1 to 6, wherein no more than 30% loss in extracellular proteolytic activity occurs over 2, 3, 6, 12, 18, 24 or 36 months at 5° C.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

A liquid composition according to any one of claims 1 to 7, wherein said proteinaceous neurotoxin is a botulinum neurotoxin, selected from a natural botulinum neurotoxin in complex form, a high purity natural botulinum neurotoxin and a recombinant botulinum neurotoxin.

### Claim 9 (depends on 8)

A liquid composition according to claim 8, wherein said botulinum neurotoxin is a recombinant botulinum neurotoxin selected from a botulinum neurotoxin A, B, C, D, E, For G, a modified botulinum neurotoxin and a chimeric botulinum neurotoxin.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

A liquid composition according to any one of claims 1 to 9, wherein said liquid composition comprises:
4 to 10000 LD50 units of botulinum neurotoxin per mL,
0.001 to 15% v/v polysorbate,
0.1 to 5 mg/mL tryptophan,
10 to 500 mM NaCl,
1 to 50 mM KCl,
1 to 100 mM Sodium phosphate,
has a pH between 5.5 and 8, and is stable for 6 months at 5° C.

### Claim 11 (depends on 10)

A liquid composition according to claim 10, wherein said liquid composition comprises:
10 to 2000 LD50 units of botulinum neurotoxin per mL,
0.05 to 0.2% v/v polysorbate 80,
0.1 to 5 mg/mL tryptophan,
25 to 300 mM NaCl,
1 to 10 mM KCl,
2 to 50 mM Sodium phosphate,
has a pH between 6.0 and 7.5, and is stable for 12 months at 5° C.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

A liquid composition according to any one of claims 1 to 11 for use in therapy.

### Claim 13 (depends on 12)

A liquid composition according to claim 12 for use in treating or preventing muscular disorders, neuromuscular disorders, neurological disorders, ophthalmological disorders, pain disorders, psychological disorders, articular disorders, inflammatory disorders, endocrine disorders or urological disorders.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

Use of liquid composition according to any one of claims 1 to 11 in aesthetic medicine, for example for treating or preventing skin wrinkles, in particular facial wrinkles such as facial frown lines, wrinkles of the contour of the eye, glabellar frown lines, downturned mouth, wrinkles of the neck (platysmal bands), wrinkles of the chin (mentalis, peau d'orange, dimpled chin), forehead lines, “scratched skin” wrinkles, nasal lift treatment or sleep lines.

### Claim 15

Use of an amino acid selected from tryptophan and tyrosine to protect a proteinaceous neurotoxin from degradation in a liquid composition which is free of animal derived proteins.

### Claim 16 (depends on 15)

Use according to claim 15, wherein said amino acid is tryptophan.

### Claim 17 (depends on 15, 16)

Use according to claim 15 or 16, wherein said proteinaceous neurotoxin is a botulinum neurotoxin.

### Claim 18 (depends on 15)

Use according to claim 15, wherein said amino acid is used in combination with a surfactant and a buffer comprising sodium, chloride and phosphate ions, and said liquid composition has a pH between 5.5 and 8.
